Shares in Zentalis Pharmaceuticals Inc. rose sharply after Pfizer Inc. invested $25 million and struck a deal to catalyze development of the company’s WEE1 inhibitor ZN-c3, an oral drug designed to make cancer cells self-destruct.
Zentera Therapeutics Inc. completed a $75 million series B financing round to help further its candidates in China, as it paves the way for a listing in Hong Kong next year.
HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.
HONG KONG – New York and San Diego-based Zentalis Pharmaceuticals Inc. has gained $20 million in a series A financing round to support a Chinese joint venture called Zentera Therapeutics.
